Drugs / BRL-101
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05577312 | Nov 2022 → Aug 2026 overdue | beta thalassemia | Bioray Laboratories | Enrolling by invitation | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06300723 | Jul 2024 → Mar 2026 | sickle cell disease | Bioray Laboratories | Unknown | No outcome recorded |
| — | NCT06287086 | Jun 2024 → Aug 2025 | sickle cell disease | Bioray Laboratories | Unknown | No outcome recorded |
| — | NCT06287099 | Apr 2024 → Oct 2025 | sickle cell disease | Bioray Laboratories | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | BRL Medicine Inc. | Results 六年长期随访持续验证疗效持久性：邦耀生物BRL-101基因编辑疗法治疗地贫取得重要进展 brlmed.com ↗
经过持续六年随访，该患儿目前仍保持摆脱输血依赖状态，血红蛋白水平维持在约140 g/L（处于其年龄和性别对应的正常参考范围），整体健康状况良好，生长发育符合年龄阶段预期。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | BRL Medicine Inc. | 六年长期随访持续验证疗效持久性：邦耀生物BRL-101基因编辑疗法治疗地贫取得重要进展 brlmed.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRL-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05577312 ↗ |
| Modality | Cell therapy | “autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (BRL-101)” NCT05577312 ↗ |
| Route | Intravenous | “administered as a single intravenous infusion” NCT05577312 ↗ |
| Target | BCL11A | “CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site” NCT05577312 ↗ |